Christine Nguyen

Christine Nguyen

Auto-generated profile, based on publicly available information

Christine Nguyen

Human Stem Cell Research Center-HSC, Ho Chi Minh City,Vietnam

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
AKAnusha Kalbasi
Anusha Kalbasi
MTMito Tariveranmoshabad
Mito Tariveranmoshabad
KHKevin Hakimi
Kevin Hakimi
SKSarah Kremer
Sarah Kremer
KCKatie M. Campbell
Katie M. Campbell
ARAntoni Ribas
Antoni Ribas
Interferon-independent MHC class I induction restores T cell immunity.

1 May 2021 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
CICiro Gargiulo Isacco
Ciro Gargiulo Isacco
ABAndrea Ballini
Andrea Ballini
DANILA DE VITODANILA DE VITO
DANILA DE VITO
KNKieu Cao Diem Nguyen
Kieu Cao Diem Nguyen
SCStefania Cantore
Stefania Cantore
Francesco InchingoloFrancesco Inchingolo
Francesco Inchingolo
The current treatment and prevention of oral disorders follow a very sectoral control and procedures considering mouth and its structures as system completely independent from the rest of the body. The main therapeutic approach is carried out on just to keep the levels of oral bacteria and hygiene in an acceptable range compatible with one-way vision of oral-mouth health completely separated from a systemic microbial homeostasis (eubiosis vs dysbiosis). This can negatively impact on the diagnosis of more complex systemic disease and its progression. Dysbiosis is consequence of oral and gut microbiota unbalance with consequences, as reported in current literature, in cardio vascular disease, diabetes mellitus, rheumatoid arthritis, and Alzheimer’s disease. Likewise, there is the need to highlight and develop a novel philosophical approach in the treatments for oral diseases that will necessarily involve non-conventional approaches.

18 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
JNJean Philippe Nesseler
Jean Philippe Nesseler
MLMi-Heon Lee
Mi-Heon Lee
CNChristine Nguyen
Christine Nguyen
AKAnusha Kalbasi
Anusha Kalbasi
JSJames W. Sayre
James W. Sayre
DSDörthe Schaue
Dörthe Schaue
The purpose of this study was to determine the dynamic contributions of different immune cell subsets to primary and abscopal tumor regression after hypofractionated radiation therapy (hRT) and the impact of anti-PD-1 therapy. A bilateral syngeneic FSA1 fibrosarcoma model was used in immunocompetent C3H mice, with delayed inoculation to mimic primary and microscopic disease. The effect of tumor burden on intratumoral and splenic immune cell content was delineated as a prelude to hRT on macroscopic T1 tumors with 3 fractions of 8 Gy while microscopic T2 tumors were left untreated. This was performed with and without systemic anti-PD-1. Immune profiles within T1 and T2 tumors and in spleen changed drastically with tumor burden in untreated mice with infiltrating CD4+ content declining, while the proportion of CD4+ Tregs rose. Myeloid cell representation escalated in larger tumors, resulting in major decreases in the lymphoid:myeloid ratios. In general, activation of Tregs and myeloid-derived suppressor cells allow immunogenic tumors to grow, although their relative contributions change with time. The evidence suggests that primary T1 tumors self-regulate their immune content depending on their size and this can influence the lymphoid compartment of T2 tumors, especially with respect to Tregs. Tumor burden is a major confounding factor in immune analysis that has to be taken into consideration in experimental models and in the clinic. hRT caused complete local regression of primary tumors, which was accompanied by heavy infiltration of CD8+ T cells activated to express IFN-γ and PD-1; while certain myeloid populations diminished. In spite of this active infiltrate, primary hRT failed to generate the systemic conditions required to cause abscopal regression of unirradiated microscopic tumors unless PD-1 blockade, which on its own was ineffective, was added to the RT regimen. The combination further increased local and systemically activated CD8+ T cells, but few other changes. This study emphasizes the subtle interplay between the immune system and tumors as they grow and how difficult it is for local RT, which can generate a local immune response that may help with primary tumor regression, to overcome the systemic barriers that are generated so as to effect immune regression of even small abscopal lesions.

1 July 2017 in British Journal of Radiology
Verified
Journal Article
Open access
WMWilliam McBride
William McBride
EGEkambaram Ganapathy
Ekambaram Ganapathy
MLMi-Heon Lee
Mi-Heon Lee
JNJean P Nesseler
Jean P Nesseler
CNChristine Nguyen
Christine Nguyen
DSDörthe Schaue
Dörthe Schaue
The advent and success of immune checkpoint inhibitors (ICIs) in cancer treatment has broadened the spectrum of tumours that might be considered “immunogenic” and susceptible to immunotherapeutic (IT) intervention. Not all cancer types are sensitive, and not all patients with any given type respond. Combination treatment of ICIs with an established cytotoxic modality such as radiation therapy (RT) is a logical step towards improvement. For one, RT alone has been shown to be genuinely immunomodulatory and secondly pre-clinical data generally support combined ICI-RT approaches. This new integrated therapy for cancer treatment holds much promise, although there is still a lot to be learned about how best to schedule the treatments, manage the toxicities and determine what biomarkers might predict response, as well as many other issues. This review examines how RT alters the immune rheostat and how it might best be positioned to fully exploit IT.